000808538 001__ 808538
000808538 005__ 20210129222808.0
000808538 0247_ $$2doi$$a10.2217/fon.15.334
000808538 0247_ $$2ISSN$$a1479-6694
000808538 0247_ $$2ISSN$$a1744-8301
000808538 0247_ $$2WOS$$aWOS:000370695600008
000808538 037__ $$aFZJ-2016-02276
000808538 041__ $$aEnglish
000808538 082__ $$a610
000808538 1001_ $$0P:(DE-HGF)0$$aPinkawa, Michael$$b0$$eCorresponding author
000808538 245__ $$aPrediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients
000808538 260__ $$aLondon$$bFuture Medicine Ltd$$c2016
000808538 3367_ $$2DRIVER$$aarticle
000808538 3367_ $$2DataCite$$aOutput Types/Journal article
000808538 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1506327376_17752
000808538 3367_ $$2BibTeX$$aARTICLE
000808538 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000808538 3367_ $$00$$2EndNote$$aJournal Article
000808538 520__ $$aAim: To identify predictive assays for radiation-induced toxicity in prostate cancer patients.Patients & methods: Patients have been surveyed prospectively before and up to 16 monthsafter radiotherapy using a validated questionnaire. Subgroups of 25 patients with minorand larger score changes, respectively, were selected for γ-H2AX, G2 and Annexin V assays.Results: A significantly higher spontaneous chromatid aberration yield (HR: 1.46 [95% CI:1.02–2.09]; p = 0.04), higher levels of early apoptotic (HR: 1.12 [95% CI: 1.01–1.24]; p = 0.04) andlate apoptotic and necrotic (HR: 1.10 [95% CI: 0.99–1.23]; p = 0.08) lymphocytes 24-h postirradiationwere found in patients with a bowel bother score decrease greater than 20 pointsmore than 1 year after treatment. Conclusion: Chromatid aberration and apoptosis/necrosisassays appear to be suitable for the prediction of radiation-induced toxicity.
000808538 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000808538 588__ $$aDataset connected to CrossRef
000808538 65027 $$0V:(DE-MLZ)SciArea-190$$2V:(DE-HGF)$$aMedicine$$x0
000808538 7001_ $$0P:(DE-HGF)0$$aBrzozowska, Kinga$$b1
000808538 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, Ralf$$b2$$ufzj
000808538 7001_ $$0P:(DE-HGF)0$$aEble, Michael J$$b3
000808538 7001_ $$0P:(DE-Juel1)133346$$aSchmitz, Sabine$$b4$$ufzj
000808538 773__ $$0PERI:(DE-600)2184533-5$$a10.2217/fon.15.334$$gVol. 12, no. 5, p. 617 - 624$$n5$$p617 - 624$$tFuture oncology$$v12$$x1744-8301$$y2016
000808538 909CO $$ooai:juser.fz-juelich.de:808538$$pVDB
000808538 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich$$b2$$kFZJ
000808538 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133346$$aForschungszentrum Jülich$$b4$$kFZJ
000808538 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000808538 9141_ $$y2017
000808538 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000808538 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000808538 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000808538 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFUTURE ONCOL : 2014
000808538 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000808538 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000808538 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000808538 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000808538 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000808538 920__ $$lyes
000808538 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
000808538 980__ $$ajournal
000808538 980__ $$aVDB
000808538 980__ $$aI:(DE-Juel1)S-US-20090406
000808538 980__ $$aUNRESTRICTED